The best evidence so far of the importance of the Wnt pathway to CSCs biology has been reported in myeloid leukaemia, but its contribution has also been reported in the maintenance of the CSCs of melanoma, breast, colon, and lung cancers.12, 26 Therefore, with regard to inhibiting the common upstream regulator of Wnt/β‐catenin signalling, Gal‐3 may be an effective target for cancer stem cell therapy. This evidence concerns the gene LGALS3 and myeloid leukemia.